Multivariable linear mixed effects models: independent predictors of HIV-1 RNA levels (log₁₀ copies/mL) and CD4+ lymphocyte counts (cells/mm³) during 6 months following first HAART initiation^*^&.

Note: 95% CI: 95% confidence interval. HAART: highly active antiretroviral therapy. CD4+ lymphocyte count nadir: the lowest CD4+ lymphocyte count while in care. ADE: AIDS-defining event. Non-HAART ART: non-HAART antiretroviral therapy. *Mixed effect model adjusted for baseline CD4+ lymphocyte count and HIV-1 RNA level, age, race, CD4+ lymphocyte count nadir, prior ADE, prior use of non-HAART ART, HAART type, prior pregnancies, and date of HAART initiation. &The reference group was women who started HAART during pregnancy. **Interaction terms are equal to the difference in slopes of HIV-1 RNA and CD4+ lymphocyte changes between women who started HAART during pregnancy and those who started HAART before or after pregnancy.